We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+88.59%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
+$539M
Cap. Flow
+$86.9M
Cap. Flow %
5.25%
Top 10 Hldgs %
47.9%
Holding
83
New
24
Increased
15
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$46.6M
2
TNGX icon
Tango Therapeutics
TNGX
+$28M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
4
IMVT icon
Immunovant
IMVT
+$24.5M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.6M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$57M
2
ARVN icon
Arvinas
ARVN
+$47.5M
3
DYN icon
Dyne Therapeutics
DYN
+$21.8M
4
VSTM icon
Verastem
VSTM
+$20.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
2 Miscellaneous 9.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$159M 9.63%
2,000,000
+250,000
+14% +$16.4M
PRAX icon
2
Praxis Precision Medicines
PRAX
$9.63B
$111M 6.68%
375,000
+250,000
+200% +$46.6M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.87B
$108M 6.53%
3,125,000
+875,000
+39% +$27.9M
OLMA icon
4
Olema Pharmaceuticals
OLMA
$899M
$80.2M 4.85%
3,208,875
– –
RVMD icon
5
CALL
Revolution Medicines
RVMD
$44.6B
$79.7M 4.81%
1,000,000
– –
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
$68.5M 4.14%
310,000
-65,000
-17% -$10.5M
ABVX
7
Abivax
ABVX
$9.89B
$53.9M 3.26%
400,000
-15,000
-4% -$1.64M
ERAS icon
8
Erasca
ERAS
$6.31B
$48.4M 2.92%
13,000,000
-2,150,000
-14% -$6.05M
OCUL icon
9
Ocular Therapeutix
OCUL
$2.28B
$42.5M 2.57%
3,500,000
+250,000
+8% +$3.04M
GPCR icon
10
Structure Therapeutics
GPCR
$3.38B
$41.7M 2.52%
600,000
-250,000
-29% -$10.2M
IRON icon
11
Disc Medicine
IRON
$3.07B
$40.5M 2.45%
510,000
+60,000
+13% +$5.07M
MAZE
12
Maze Therapeutics
MAZE
$1.52B
$39.4M 2.38%
950,000
-277,300
-23% -$9.53M
TNGX icon
13
Tango Therapeutics
TNGX
$3.94B
$37.2M 2.25%
4,200,000
+3,250,000
+342% +$28M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$36.1M 2.18%
500,000
-100,000
-17% -$6.46M
BIIB icon
15
Biogen
BIIB
$32.3B
$35.2M 2.13%
200,000
+100,000
+100% +$16.3M
IMVT icon
16
Immunovant
IMVT
$8.51B
$35M 2.11%
1,375,000
+1,100,000
+400% +$24.5M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.9B
$34M 2.05%
200,000
– –
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$30.3M 1.83%
+750,000
New +$17.3M
PCVX icon
19
Vaxcyte
PCVX
$8.9B
$30M 1.81%
650,000
+25,000
+4% +$1.12M
IMCR icon
20
Immunocore
IMCR
$1.89B
$29.5M 1.78%
850,000
– –
LBRX
21
LB Pharmaceuticals
LBRX
$1.54B
$26.7M 1.61%
1,200,000
+70,000
+6% +$1.22M
APLS
22
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$25.1M 1.52%
1,000,000
– –
RCUS icon
23
CALL
Arcus Biosciences
RCUS
$3.72B
$25M 1.51%
+1,050,000
New +$21.4M
DYN icon
24
Dyne Therapeutics
DYN
$4.68B
$24.4M 1.48%
1,250,000
-1,150,000
-48% -$21.8M
DSGN icon
25
Design Therapeutics
DSGN
$946M
$23.4M 1.42%
2,500,000
-1,155,000
-32% -$9.04M
1
2 3 4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q4 2025 Portfolio in Review

As of Q4 2025, Logos Global Management held 83 positions worth $1.65B, up 48% from $1.12B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management deployed $86.9M of net new capital in Q4 2025, opening 24 new positions and adding to 15 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.8M trimmed.

  • Logos Global Management's largest Q4 2025 buy was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.
  • Logos Global Management added most to Praxis Precision Medicines in Q4 2025, an estimated $46.6M increase.
  • Logos Global Management's biggest Q4 2025 reduction was Dyne Therapeutics, cutting an estimated $21.8M.
  • Logos Global Management fully exited Akero Therapeutics in Q4 2025, selling an estimated $57M.
  • Logos Global Management's ten largest holdings make up 48% of its $1.65B portfolio in Q4 2025.
  • Logos Global Management opened 24 new positions and closed 14 in Q4 2025.
  • Logos Global Management's portfolio value rose 48% quarter-over-quarter to $1.65B.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.